Pimecrolimus Interferes With the Therapeutic Efficacy of Human Mesenchymal Stem Cells in Atopic Dermatitis by Regulating NFAT-COX2 Signaling

    August 2021 in “ Stem Cell Research & Therapy ”
    Nari Shin, Namhee Jung, Seung‐Eun Lee, Dasom Kong, Nam Gyo Kim, Myung Geun Kook, Hwanhee Park, Soon Won Choi, Seunghee Lee, Kyung‐Sun Kang
    TLDR Pimecrolimus reduces the effectiveness of stem cell therapy for atopic dermatitis.
    The study found that pimecrolimus, a calcineurin inhibitor used for atopic dermatitis (AD), reduced the therapeutic efficacy of human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) in a mouse model. Pimecrolimus interfered with the stem cells' ability to modulate immune responses by inhibiting the nuclear translocation of NFAT3, crucial for COX2-mediated immunomodulation. This disruption affected the reduction of epidermal thickness and mast cell infiltration, key therapeutic effects of hUCB-MSCs. The findings highlighted the importance of considering drug interactions in MSC-based therapies for AD, as the combination therapy was less effective than hUCB-MSCs alone.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results